Eman G Khedr, Nahla E El Ashmawy, Hoda A El Bahrawy and Samar M Al Tantawy
Tanta University, Egypt
Posters & Accepted Abstracts: Pharmaceut Reg Affairs
Bladder cancer remains a huge concern for the medical community because of its incidence and prevalence rates, as well as high percentage of recurrence and progression. Omegaâ��3 polyunsatu�¬rated fatty acids (nâ��3 PUFAs) and atorvastatin (ATOR) proved anti-inflammatory effects through PPAR-�³ mechanism. However, their chemopreventive effect still remained to be examined and clari�¬fied. In the current study, bladder cancer was induced in rats by the chemical carcinogen BBN. n-3 PUFAs (DHA and EPA 2:3 w/w; 1200 mg/kg) and/or ATOR (6 mg/kg) were given orally daily to rats for 8 consecutive weeks concomitantly with BBN, and continued for further 4 weeks after cessa-tion of BBN administration. The histopathological examination of rat bladder revealed presence of tumors and absence of apoptotic bodies in sections from BBN group, while tumors were absent and apoptotic bodies were clearly observed in sections from rat groups treated with n-3 PUFAs, ATOR, or both drugs. The study of the molecular mechanisms illustrated downregulation of COX-2 and P53 (mutant) genes and suppression of TGFâ���²1 and the lipid peroxidation product malondialdehyde in serum of rats of the three treated groups. This chemopreventive effect was confirmed by and associ�¬ated with lower level of bladder tumor antigen (BTA) in urine. However, the combined treatment with both drugs exhibited the major protective effect and nearly corrected the dyslipidemia that has been induced by BBN. Collectively, n-3PUFAs and ATOR, besides having anti-inflammatory proper-ties, proved a chemopreventive effect against bladder cancer, which nominates them to be used as adjuvant therapy with other chemotherapeutics.
Pharmaceutical Regulatory Affairs: Open Access received 533 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 